Home›Trial›NCT06113445
🔬NCT06113445Phase 3ACTIVE NOT RECRUITING

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

Study Summary

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Conditions
NonSegmental Vitiligo
Interventions / Drugs
PovorcitinibPlacebo
View on ClinicalTrials.gov ↗
Sponsor
INCY
Incyte Corporation
Oncology
C60/100
Study Details
Enrollment467 participants
Primary Completion—
Lead SponsorIncyte Corporation
Data Retrieved2026-04-11 02:55:29.647833+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.